Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019
Introduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province. Objective: to evaluate the therapeutic results of the application of botulinum toxin type A in patients with hemifacial spasm t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Universidad de Ciencias Médicas de Guantánamo
2020-10-01
|
| Series: | Revista Información Científica |
| Subjects: | |
| Online Access: | http://www.revinfcientifica.sld.cu/index.php/ric/article/view/3027 |
| _version_ | 1797728682252435456 |
|---|---|
| author | Talía Marzo-Ramírez Tamara Mecías-Díaz |
| author_facet | Talía Marzo-Ramírez Tamara Mecías-Díaz |
| author_sort | Talía Marzo-Ramírez |
| collection | DOAJ |
| description | Introduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province.
Objective: to evaluate the therapeutic results of the application of botulinum toxin type A in patients with hemifacial spasm treated in a Neurology consultation.
Method: a descriptive and longitudinal study was carried out in 21 patients attended in Neurology service with hemifacial spasm and botulinum toxin type A treatment, from January 2018 to January 2019. The variables studied were: age, gender, hemiface affected, latency period, duration, disappearance of the clinical effects of botulinum toxin type A, and percentage of functional disability in patients when applying the disability scale before and after the treatment.
Results: female cases predominated (57.1%), ages over 55 years (57.14 %), the most common affected side of the face was the left, with 57.14 %, the latency period of botulinum toxin type A was between the third to the tenth day in 14 of the patients (66.67 %), the maximum time of duration of treatment ranged from one to two months (57.14 %), and the disappearance of the therapeutic effect of the toxin in the patients was between the third to the fourth month (52.38%). After the application of the clinical assessment scale of hemifacial spasm, a decrease in the percentage of patients with functional disability was evidenced.
Conclusions: botulinum toxin type A is effective in the treatment of hemifacial spasm. |
| first_indexed | 2024-03-12T11:17:32Z |
| format | Article |
| id | doaj.art-3fe5cf6d67b7481794fe9a4383cc0143 |
| institution | Directory Open Access Journal |
| issn | 1028-9933 1028-9933 |
| language | Spanish |
| last_indexed | 2024-03-12T11:17:32Z |
| publishDate | 2020-10-01 |
| publisher | Universidad de Ciencias Médicas de Guantánamo |
| record_format | Article |
| series | Revista Información Científica |
| spelling | doaj.art-3fe5cf6d67b7481794fe9a4383cc01432023-09-02T01:41:46ZspaUniversidad de Ciencias Médicas de GuantánamoRevista Información Científica1028-99331028-99332020-10-019943593662095Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019Talía Marzo-Ramírez0Tamara Mecías-Díaz1Hospital General Docente “Dr. Agostinho Neto”, GuantánamoHospital General Docente “Dr. Agostinho Neto”, GuantánamoIntroduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province. Objective: to evaluate the therapeutic results of the application of botulinum toxin type A in patients with hemifacial spasm treated in a Neurology consultation. Method: a descriptive and longitudinal study was carried out in 21 patients attended in Neurology service with hemifacial spasm and botulinum toxin type A treatment, from January 2018 to January 2019. The variables studied were: age, gender, hemiface affected, latency period, duration, disappearance of the clinical effects of botulinum toxin type A, and percentage of functional disability in patients when applying the disability scale before and after the treatment. Results: female cases predominated (57.1%), ages over 55 years (57.14 %), the most common affected side of the face was the left, with 57.14 %, the latency period of botulinum toxin type A was between the third to the tenth day in 14 of the patients (66.67 %), the maximum time of duration of treatment ranged from one to two months (57.14 %), and the disappearance of the therapeutic effect of the toxin in the patients was between the third to the fourth month (52.38%). After the application of the clinical assessment scale of hemifacial spasm, a decrease in the percentage of patients with functional disability was evidenced. Conclusions: botulinum toxin type A is effective in the treatment of hemifacial spasm.http://www.revinfcientifica.sld.cu/index.php/ric/article/view/3027trastorno del movimientotoxina botulínicaespasmo hemifacial |
| spellingShingle | Talía Marzo-Ramírez Tamara Mecías-Díaz Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 Revista Información Científica trastorno del movimiento toxina botulínica espasmo hemifacial |
| title | Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 |
| title_full | Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 |
| title_fullStr | Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 |
| title_full_unstemmed | Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 |
| title_short | Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019 |
| title_sort | botulinum toxin type a efficient treatment in patients with hemifacial spasm guantanamo 2018 2019 |
| topic | trastorno del movimiento toxina botulínica espasmo hemifacial |
| url | http://www.revinfcientifica.sld.cu/index.php/ric/article/view/3027 |
| work_keys_str_mv | AT taliamarzoramirez botulinumtoxintypeaefficienttreatmentinpatientswithhemifacialspasmguantanamo20182019 AT tamarameciasdiaz botulinumtoxintypeaefficienttreatmentinpatientswithhemifacialspasmguantanamo20182019 |